VNDA
NASD Vanda Pharmaceuticals Inc.$5.17 ↑ +0.00 (+0.00%) Trading Up from the previous close of $5.17, and at the day’s high of $5.17
- YTD change
- -41.38%
- vs 20-day SMA
- -0.51%
- vs 200-day SMA
- -21.31%
Price ranges
Price & Performance
-1.48 (-22.26%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 84.5% away from all-time highs of $33.44
- VNDA is down 41% since the beginning of the year
- VNDA is up 1% over the past 12 months
- VNDA is down 5% over the past 1 month
- 13% of all VNDA investors are betting against VNDA
VNDA reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +5.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.02
- Last 5 days
- +0.78%
- vs 8-day SMA
- +1.68%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
